NCT00098254View on ClinicalTrials.gov

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

November 30, 2009

Study Completion Date

January 31, 2011

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

BAY 43-9006 (Sorafenib)

Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00098254 - BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter